What is new in chemotherapy for cancer? Read our chemotherapy blog and learn more about the latest advancements in cytotoxic therapy for several cancers.

First-line Nivolumab-Ipilimumab in TMB-high NSCLC front-line immunotherapy for non-small cell lung cancer tumour-mutation burden CheckMate 227 NCT02477826

Nivolumab-Ipilimumab Combination: A New Option for TMB-High NSCLC (CheckMate 227)

First-line nivolumab-ipilimumab in TMB-high NSCLC with was associated with a more than tripled 1-year progression-free survival (PFS) rate compared to platinum-based chemotherapy in the Phase III CheckMate 227 trial (NCT02477826).

NCT02578680 Keynote189 pembrolizumab chemotherapy nsclc NEJM Leena Gandhi

Frontline Combination of Pembrolizumab and Chemotherapy: A New Standard of Care for Nonsquamous NSCLC

Frontline pembrolizumab (KeytrudaⓇ) plus standard platinum-based chemotherapy reduces the risk of death by more than 50% in patients with nonsquamous non–small cell lung cancer (NSCLC) not harbouring EGFR or ALK genetic aberrations, as shown by the Phase III KEYNOTE-189 (NCT02578680).

Keynote-042 Keynote-024 pembrolizumab nsclc keytruda nsclc non-squamous squamous PD-L1 expression 1% 20% 50% Tony Mok MD NCT02220894 Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

Pembrolizumab effective in frontline NSCLC with low PD-L1 expression

Pembrolizumab (Keytruda®) as single-agent immunotherapy in the frontline setting of any histology NSCLC with a PD-L1 expression ≥1% was associated with improved overall survival (OS) when compared to platinum-doublet chemotherapy in the KEYNOTE-042.

Symposium Highlight 5HT3 NK1 Palonosetron Netupitant CINV Chemotherapy-induced Nausea and Vomiting

Advances in the Prophylaxis of Chemotherapy-Induced Nausea and Vomiting: From Multi-Dose to Single Dose Control

There is no excerpt because this is a protected post.